Supplementary Materials

Supplementary Material for:

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

Manuel Fankhauser, Maria A. S. Broggi, Lambert Potin, Natacha Bordry, Laura Jeanbart, Amanda W. Lund, Elodie Da Costa, Sylvie Hauert, Marcela Rincon-Restrepo, Christopher Tremblay, Elena Cabello, Krisztian Homicsko, Olivier Michielin, Douglas Hanahan, Daniel E. Speiser, Melody A. Swartz*

*Corresponding author. Email: melodyswartz{at}uchicago.edu

Published 13 September 2017, Sci. Transl. Med. 9, eaal4712 (2017)
DOI: 10.1126/scitranslmed.aal4712

This PDF file includes:

  • Materials and Methods
  • Fig. S1. VEGF-C/VEGFR-3 signaling does not affect the growth of B16 melanomas, and only potentiates immunotherapy in lymphangiogenic tumors, including those that do not express OVA.
  • Fig. S2. In the naturally lymphangiogenic BrafV600E/Pten−/− mouse model, VEGFR-3 blockade reduces intratumoral lymphatics and total CCL21 in the tumor microenvironment.
  • Fig. S3. Expression of VEGFC, but not FIGF (VEGFD) or VEGFA, strongly correlates with hallmarks of inflammation within metastatic sites of human melanoma.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Primary data.

[Download Table S1]